Difference between revisions of "Stiegler"
| Line 2: | Line 2: | ||
<span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:"><span style="color:black">No difference in tinnitus outcome between two hyperbaric oxygen protocols</span></span></span>'''</span> | <span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:"><span style="color:black">No difference in tinnitus outcome between two hyperbaric oxygen protocols</span></span></span>'''</span> | ||
| − | {| class="Table" style="width: | + | {| class="Table" style="width: 589px;" width="0" |
|- | |- | ||
| − | | style="width: | + | | style="width: 579px;" width="548" | |
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">1. There was no difference in outcome depending on the HBOT protocol<br/> 2. No information on the efficacy of HBOT comapred to no HBOT</span></span></span>'''</span> | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">1. There was no difference in outcome depending on the HBOT protocol<br/> 2. No information on the efficacy of HBOT comapred to no HBOT</span></span></span>'''</span> | ||
| Line 17: | Line 17: | ||
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">The Evidence:</span></span></span>'''</span> | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">The Evidence:</span></span></span>'''</span> | ||
| − | {| class="Table" style=" | + | {| class="Table" style="width: 666px;" |
|- | |- | ||
| − | | style="width:96.6pt" width="132" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">Outcome</span></span>'''</span></p> | + | | style="width:96.6pt" width="132" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Outcome</span></span>'''</span></p> |
| − | | style="width:48.1pt" width="66" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">Time to Outcome</span></span>'''</span></p> | + | | style="width:48.1pt" width="66" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Time to Outcome</span></span>'''</span></p> |
| − | | style="width:41.05pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">2.2 ATA rate</span></span>'''</span></p> | + | | style="width:41.05pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">2.2 ATA rate</span></span>'''</span></p> |
| − | | style="width:41.0pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">2.5 ATA rate</span></span>'''</span></p> | + | | style="width:41.0pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">2.5 ATA rate</span></span>'''</span></p> |
| − | | style="width:62.3pt" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">Relative risk reduction</span></span>'''</span></p> | + | | style="width:62.3pt" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Relative risk reduction</span></span>'''</span></p> |
| − | | style="width: | + | | style="width: 96px;" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Absolute risk difference</span></span>'''</span></p> |
| − | | style="width: | + | | style="width: 140px;" width="119" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">NNT</span></span>'''</span></p> |
|- | |- | ||
| − | | rowspan="2" style="width:96.6pt" width="132" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">Improved or resolved after treatment</span></span>'''</span></p> | + | | rowspan="2" style="width:96.6pt" width="132" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Improved or resolved after treatment</span></span>'''</span></p> |
| − | | style="width:48.1pt" width="66" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">1 month</span></span>'''</span></p> | + | | style="width:48.1pt" width="66" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">1 month</span></span>'''</span></p> |
| − | | style="width:41.05pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">0.49</span></span>'''</span></p> | + | | style="width:41.05pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">0.49</span></span>'''</span></p> |
| − | | style="width:41.0pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">0.48</span></span>'''</span></p> | + | | style="width:41.0pt" width="57" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">0.48</span></span>'''</span></p> |
| − | | style="width:62.3pt" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:">2%</span></span>'''</span></p> | + | | style="width:62.3pt" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">2%</span></span>'''</span></p> |
| − | | style="width: | + | | style="width: 96px;" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">0.01</span></span>'''</span></p> |
| − | | style="width: | + | | style="width: 140px;" width="119" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">83</span></span>'''</span></p> |
|- | |- | ||
| − | | colspan="3" style="width:133.15pt" width="180" | <p align="right" style="margin-bottom:.0001pt; text-align:right; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:">95% CIs:</span></span></span></p> | + | | colspan="3" style="width:133.15pt" width="180" | <p align="right" style="margin-bottom:.0001pt; text-align:right; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">95% CIs:</span></span></span></p> |
| − | | style="width:62.3pt" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:">-20% to 25%</span></span></span></p> | + | | style="width:62.3pt" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">-20% to 25%</span></span></span></p> |
| − | | style="width: | + | | style="width: 96px;" width="85" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">-0.099 to 0.123</span></span></span></p> |
| − | | style="width: | + | | style="width: 140px;" width="119" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">NNT = 8 to INF; NNH = 10 to INF</span></span></span></p> |
|} | |} | ||
| − | |||
| − | |||
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">Comments:</span></span></span>'''<br/> <span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">1. 360 patients treated in the whole cohort, but only 312 had outcomes recorded. It is not clear why.<br/> 2. No comparison made between HBOT and no HBOT in this study.<br/> 3. Randomisation method not specified and no other randomised outcomes reported.<br/> 4. Authors suggest the outcome is dependent on expectations for success prior to treatment</span></span></span></span> | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">Comments:</span></span></span>'''<br/> <span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">1. 360 patients treated in the whole cohort, but only 312 had outcomes recorded. It is not clear why.<br/> 2. No comparison made between HBOT and no HBOT in this study.<br/> 3. Randomisation method not specified and no other randomised outcomes reported.<br/> 4. Authors suggest the outcome is dependent on expectations for success prior to treatment</span></span></span></span> | ||
| Line 47: | Line 45: | ||
<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">Appraised by: Mike Bennett m.bennett@unsw.edu.au; Sunday, 5 January 2020<br/> Email:<br/> '''Kill or Update By:''' January 2023</span></span></span></span> | <span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:"><span style="color:black">Appraised by: Mike Bennett m.bennett@unsw.edu.au; Sunday, 5 January 2020<br/> Email:<br/> '''Kill or Update By:''' January 2023</span></span></span></span> | ||
| − | * | + | * |
<p style="text-align: center;">[[File:Sumhorsa.gif|center|Sumhorsa.gif]]</p> <p style="text-align: center;"><span style="font-size:xx-large;">[[Audiovestibular|BACK]]</span></p> <p style="text-align: center;"> </p> | <p style="text-align: center;">[[File:Sumhorsa.gif|center|Sumhorsa.gif]]</p> <p style="text-align: center;"><span style="font-size:xx-large;">[[Audiovestibular|BACK]]</span></p> <p style="text-align: center;"> </p> | ||
Revision as of 01:55, 6 January 2020
No difference in tinnitus outcome between two hyperbaric oxygen protocols
|
1. There was no difference in outcome depending on the HBOT protocol |
Citation/s:1. Stiegler P, Matzi V, Lipp C, Kontaxis A, Klemen H, Walch C, Smolle-Jüttner F. Hyperbaric oxygen (HBO2) in tinnitus: influence of psychological factors ontreatment results? Undersea Hyperb Med. 2006 Nov-Dec;33(6):429-37.
Lead author's name and fax: Stiegler: None given
Three-part Clinical Question:For adult patients with tinnitus, does treatment with hyperbaric oxygen at 2.2 ATA compared to 2.5 ATA result in any improvement in outcome?
Search Terms: Tinnitus, hyperbaric protocol
The Study:Non-blinded randomised controlled trial without intention-to-treat.
The Study Patients: Adult patients where a decsion has been made to treat with hyperbaric oxygen therapy
Control group (N = 156; 156 analysed): 100% oxygen treatments at 2.2ATA for 60 minutes daily for 15 consecutive days
Experimental group (N = 156; 156 analysed): Methods as above but at 2.5ATA.
The Evidence:
Outcome |
Time to Outcome |
2.2 ATA rate |
2.5 ATA rate |
Relative risk reduction |
Absolute risk difference |
NNT |
Improved or resolved after treatment |
1 month |
0.49 |
0.48 |
2% |
0.01 |
83 |
95% CIs: |
-20% to 25% |
-0.099 to 0.123 |
NNT = 8 to INF; NNH = 10 to INF | |||
Comments:
1. 360 patients treated in the whole cohort, but only 312 had outcomes recorded. It is not clear why.
2. No comparison made between HBOT and no HBOT in this study.
3. Randomisation method not specified and no other randomised outcomes reported.
4. Authors suggest the outcome is dependent on expectations for success prior to treatment
Appraised by: Mike Bennett m.bennett@unsw.edu.au; Sunday, 5 January 2020
Email:
Kill or Update By: January 2023
